Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906382 · ClinicalTrials.gov registry record · Early Phase 1
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
A Early Phase 1 study, sponsored by Floor Backes, MD.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT04906382 is a Early Phase 1 study that was terminated before completion, run by Floor Backes, MD. The registered enrollment target is 2 participants.
The verdict
NCT04906382, a Early Phase 1 study, was terminated before completion, sponsored by Floor Backes, MD.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient tumors (dMMR) may have difficulty repairing DNA mutations during replication that may affect tumor's response to therapy. Immunotherapy with monoclonal antibodies, such as tislelizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tislelizumab may help treat patients with mismatch repair deficient endometrial cancer.
Interventions
- DRUG Carboplatin
- PROCEDURE Biopsy
- DRUG Paclitaxel
- BIOLOGICAL Tislelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2022-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04906382
The ClinicalTrials.gov registry entry for NCT04906382 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Floor Backes, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT04906382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04906382 about?
NCT04906382 is a clinical study titled "Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer". This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient...
What is the current status of trial NCT04906382?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2021-07-01. Estimated completion is 2022-09-01.
What interventions are being tested in trial NCT04906382?
The interventions under investigation include: Carboplatin (DRUG), Biopsy (PROCEDURE), Paclitaxel (DRUG), Tislelizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04906382?
This trial is sponsored by Floor Backes, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.